FDA Approved: XOPENEX HFA — Supplemental Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for XOPENEX HFA (levalbuterol tartrate) submitted by Lupin Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• XOPENEX HFA (Levalbuterol tartrate)

Snippet

SUPPL AP for XOPENEX HFA (LEVALBUTEROL TARTRATE)